Adanac Molybdenum (AUAYF) 0.1210 $AUAYF TSX Venture

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Adanac Molybdenum (AUAYF) 0.1210 $AUAYF

TSX Venture Exchange Daily Bulletins
CNW Group - Wed Dec 16, 4:16PM CST
TSX VENTURE COMPANIES

Adanac Molybdenum Announces Closing of Arrangement
Marketwired - Tue Dec 15, 8:04AM CST
Adanac Molybdenum Corporation ("Adanac" or the "Company" (TSX VENTURE: AUA) is pleased to announce the completion, following the receipt of the final order of the Court on December 11, 2015, of the previously announced arrangement between Adanac and WBOX 2015-4 Ltd. (the "Purchaser" under the Business Corporations Act (British Columbia) (the "Arrangement". Pursuant to the Arrangement, the Purchaser acquired all of the issued and outstanding common shares of Adanac ("Adanac Shares", other than the Adanac Shares owned by affiliates of the Purchaser (the "Purchaser Affiliates" for a cash purchase price of $350,000 (the "Purchase Price". In addition, pursuant to the Arrangement, Adanac distributed $4.27 million in cash to Adanac shareholders as a return of capital (the "Distribution". The Purchase Price and Distribution will be delivered to Adanac shareholders, on a pro-rata basis, by Computershare Trust Company of Canada in accordance with each Adanac shareholder's duly completed, executed and deposited Letter of Transmittal, except for the Purchaser Affiliates, which will only receive their pro-rata portion of the Distribution.
AUA.VN: 0.175 (unch)

IIROC Trade Halt - Adanac Molybdenum Corporation
Newsfile Corp - Fri Dec 11, 2:15PM CST
The following issues have been halted by IIROC:

Adanac Molybdenum Mails Meeting Materials to Approve Arrangement
Marketwired - Fri Nov 06, 5:00PM CST
Adanac Molybdenum Corporation ("Adanac" or the "Company" (TSX VENTURE: AUA) is pleased to announce that it has mailed its management information circular (the "Circular" and related proxy materials to its shareholders ("Shareholders" in connection with the annual and special meeting of Shareholders to be held at 9:00 a.m. (Vancouver time) on December 8, 2015 (the "Meeting". At the Meeting, Shareholders will be asked to approve the Company's previously announced plan of arrangement (the "Plan of Arrangement" under the Business Corporations Act (British Columbia) (the "Arrangement" pursuant to which Adanac will effect a distribution of its cash holdings existing at the effective time (the "Effective Time" of the Arrangement (the "Distribution" to all Shareholders on a pro-rata basis as a return of capital and WBOX 2015-4 Ltd. ("WBOX" will subsequently acquire all of the issued and outstanding Adanac common shares (the "Adanac Shares" other than 3,618,728 Adanac Shares (the "Affiliate Shares" already owned by affiliates of WBOX for an aggregate purchase price of $350,000 (the "Purchase Price" payable in cash.
AUA.VN: 0.175 (unch)

Adanac Molybdenum Enters Definitive Arrangement Agreement
Marketwired - Tue Oct 13, 4:03PM CDT
Adanac Molybdenum Corporation ("Adanac" or the "Company" (TSX VENTURE: AUA) announces that, further to its September 11, 2015 news release in respect of its letter of intent with Whitebox Advisors, LLC ("Whitebox", it has entered into a definitive arrangement agreement (the "Arrangement Agreement" with WBOX 2015-4 Ltd. (the "Purchaser", an indirect subsidiary of Whitebox whose affiliates own an aggregate of 3,618,728 common shares of Adanac (the "Purchaser Affiliate Shares".
AUA.VN: 0.175 (unch)

IIROC Trade Resumption - Adanac Molybdenum Corporation
Newsfile Corp - Fri Sep 11, 11:55AM CDT
Trading resumes in:

Adanac Molybdenum Enters Non-Binding Letter of Intent for Sale of Company and Distribution to Shareholders
Marketwired - Fri Sep 11, 11:50AM CDT
Adanac Molybdenum Corporation ("Adanac" or the "Company" (TSX VENTURE: AUA) announces that is has entered into a letter of intent (the "Letter of Intent" with Whitebox Advisors, LLC ("Whitebox", which acts as investment advisor for several significant shareholders of the Company. The Letter of Intent sets out the intention of the Company and Whitebox (collectively, the "Parties", on a non-binding basis, to engage in negotiations to attempt to agree upon and execute a definitive agreement (the "Definitive Agreement" pursuant to which Whitebox would agree to acquire, by way of a plan of arrangement (the "Proposed Transaction", all of the issued and outstanding shares of Adanac that Whitebox does not currently own. The Letter of Intent provides for a cash purchase price of $350,000 (the "Proposed Purchase Price" which represents the value of Adanac's non-cash assets. Adanac estimates that approximately $4.3 million in cash (the "Cash Holding" would also be distributed to all shareholders, on a pro-rata return of capital basis as part of the Proposed Transaction.
AUA.VN: 0.175 (unch)

Whitebox Advisors LLC and Andrew Redleaf Cease to File Alternative Monthly Reports Regarding Adanac Molybdenum Corporation
Marketwired - Tue Sep 08, 7:32AM CDT
Whitebox Advisors LLC and Andrew Redleaf announce that they are ceasing to file alternative monthly reports under Part 4 of National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues for Adanac Molybdenum Corporation (the "Issuer" as a result of a non-binding proposal (the "Proposal" made by Whitebox Advisors LLC to the Issuer to acquire all of its issued and outstanding shares (the "Transaction".

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 75

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 324

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 90

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 345

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 209

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Forecast and Expectations for Anika Therapeutics

Updated Category News Views 118

Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...

Continue Reading
QYOU Media's Strategic Shift Towards a Creator-Focused Future

Updated Category News Views 202

QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...

Continue Reading
Understanding Recent Disclosures from Octopus Investments

Updated Category News Views 106

Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....

Continue Reading
LiTime's Innovative Battery Solutions Shine in European RV Market

Updated Category News Views 297

LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...

Continue Reading
Oncolytics Biotech Appoints Jared Kelly as New CEO to Lead Growth

Updated Category News Views 263

Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...

Continue Reading